Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane – a Pilot Study

REFERENCES

• Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol (Copenh). 2008;86(2):126–145. doi:10.1111/j.1600-0420.2007.00889.x.
   PubMed Web of Science ®Google Scholar
• Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye Lond Engl. 2019;33(7):1035–1043. doi:10.1038/s41433-019-0381-7.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Cohen FB, Aymard P, Central Serous Chorioretinopathy International Group. Multimodal imaging-based central serous chorioretinopathy classification. Ophthalmol Retina. 2020;4(11):1043–1046. doi:10.1016/j.oret.2020.07.026.
   PubMedGoogle Scholar
• Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;2015(12): CD011841. doi:10.1002/14651858.CD011841.pub2.
   PubMedGoogle Scholar
• Cardillo Piccolino F, Eandi CM, Ventre L, de la Longrais RC R, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina Phila Pa. 2003;23(6):752–763. doi:10.1097/00006982-200312000-00002.
   PubMed Web of Science ®Google Scholar
• You EL, Hébert M, Jin TS, et al. Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis. Surv Ophthalmol. Published online March 15, 2023;68(4):S0039-6257(23)00045–0. doi:10.1016/j.survophthal.2023.03.001.
   Web of Science ®Google Scholar
• Lotery A, Sivaprasad S, O’Connell A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2020;395(10220):294–303. doi:10.1016/S0140-6736(19)32981-2.
   PubMed Web of Science ®Google Scholar
• Ji S, Wei Y, Chen J, Tang S. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. Int J Clin Pharm. 2017;39(3):514–521. doi:10.1007/s11096-017-0460-4.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994–999. doi:10.1136/bjophthalmol-2021-319090.
   PubMed Web of Science ®Google Scholar
• Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157–172. doi:10.1016/j.ajo.2022.01.004.
   PubMed Web of Science ®Google Scholar
• Finger RP, Dennis N, Freitas R, et al. Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(8):3425–3448. doi:10.1007/s12325-022-02193-3.
   PubMed Web of Science ®Google Scholar
• Baumal CR, Sørensen TL, Karcher H, et al. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol (Copenh). 2023;101(2):123–139. doi:10.1111/aos.15242.
   Web of Science ®Google Scholar
• van Rijssen TJ, Mohabati D, Dijkman G, et al. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. Plos One. 2018;13(8):e0202549. doi:10.1371/journal.pone.0202549.
   PubMed Web of Science ®Google Scholar
• van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125(10):1547–1555. doi:10.1016/j.ophtha.2018.04.021.
   PubMed Web of Science ®Google Scholar
• van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022;233:101–110. doi:10.1016/j.ajo.2021.06.020.
   PubMed Web of Science ®Google Scholar
• Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2011;249(7):969–974. doi:10.1007/s00417-010-1581-9.
   PubMed Web of Science ®Google Scholar
• Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009;19(4):613–617. doi:10.1177/112067210901900415.
   PubMed Web of Science ®Google Scholar
• Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye Lond Engl. 2009;23(2):488–489. doi:10.1038/eye.2008.55.
   PubMed Web of Science ®Google Scholar
• Bae SH, Heo J, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2014;121(2):558–565. doi:10.1016/j.ophtha.2013.09.024.
   PubMed Web of Science ®Google Scholar
• Kang HM, Choi JH, Koh HJ, Lee SC, Vavvas DG. Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy. Plos One. 2020;15(9):e0238725. doi:10.1371/journal.pone.0238725.
   PubMed Web of Science ®Google Scholar
• Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye Lond Engl. quiz 741. 2015;29(6):732–740. doi:10.1038/eye.2015.58.
   PubMed Web of Science ®Google Scholar
• Kim DY, Joe SG, Yang HS, Lee JY, Kim JG, Yoon YH. SUBFOVEAL CHOROIDAL THICKNESS CHANGES in TREATED IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY and THEIR ASSOCIATION with RECURRENCE. Retina Phila Pa. 2015;35(9):1867–1874. doi:10.1097/IAE.0000000000000557.
   PubMed Web of Science ®Google Scholar
• Pitcher JD, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848–852. doi:10.1136/bjophthalmol-2014-306018.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963–976. doi:10.1016/j.ophtha.2019.12.031.
   PubMed Web of Science ®Google Scholar
• Piccolino FC, La Longrais RR D, Manea M, Cicinelli S. Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina Phila Pa. 2008;28(7):1008–1012. doi:10.1097/IAE.0b013e31816b4b86.
   PubMed Web of Science ®Google Scholar